Last updated: February 16, 2026
What is the market status of the drug NDC 68180-0699?
The NDC 68180-0699 corresponds to Ibrutinib (Imbruvica), marketed by AbbVie and Pharmacyclics. It is approved for various hematologic malignancies, primarily chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and marginal zone lymphoma. Since its market launch in 2013, Ibrutinib has dominated the targeted therapy segment for B-cell related cancers.
Market penetration remains high due to its efficacy and the sustained adoption of targeted kinase inhibitors. As of 2022, Ibrutinib generated approximately $7.8 billion in global sales, reflecting steady growth from $4.5 billion in 2018. The growth rate has moderated slightly due to patent expiry concerns, biosimilar entry, and increasing competition.
What is the current pricing landscape for Ibrutinib?
Official list prices vary regionally, but in the United States, the average wholesale price (AWP) for a 140 mg capsule typically ranges from $460 to $480 per capsule. Actual net prices paid by payers are lower due to rebates, discounts, and contract agreements. The typical dosing regimen for CLL is 420 mg daily, costing approximately $1,376 daily or roughly $503,200 annually at list prices.
In Europe and other regions, prices are generally lower. For example, in the UK, NHS negotiated prices are estimated around £40,000-£50,000 per year, benefiting from national pricing strategies.
What are the key factors influencing future pricing?
- Patent expiration and biosimilars: Patent protection was expected to expire in 2027; though patent challenges and biosimilar developments could influence prices earlier or later.
- Market competition: Multiple BTK inhibitors are in late-stage development or approved, including Zanubrutinib (BeiGene) and Acalabrutinib (AstraZeneca). These options may pressure prices downward.
- Regulatory and reimbursement policies: Increased scrutiny on drug pricing and favorable negotiations could limit future list price increases.
- Market demand: Growing indications such as Waldenström’s macroglobulinemia and potential use in other B-cell malignancies expand revenue opportunities but also attract new competitors, affecting pricing strategies.
What are the projections for future market sales and prices?
Short-term (next 3-5 years)
- Market sales are projected to stabilize or slightly decline due to biosimilar competition beginning around 2027.
- List prices are expected to diminish gradually, around 3-5% annually, driven by market pressures and negotiations.
- The net price paid by payers could decrease more sharply, approximately 10-15%, reflecting increased competition and payer cost-containment efforts.
Long-term (beyond 5 years)
- Total market revenue could decline to $4-6 billion annually by 2030 amid biosimilars and newer therapies.
- Introduction of second-generation BTK inhibitors with improved efficacy and safety profiles may further suppress prices.
Scenario analysis
| Scenario |
Likely Impact on Price |
Assumptions |
Timeframe |
| Base Case |
Moderate decrease |
Patent expiry, biosimilar entry |
2027-2030 |
| Optimistic |
Larger decrease |
Accelerated biosimilar adoption |
2028-2029 |
| Pessimistic |
Sustained high prices |
Delays in biosimilar launches |
Beyond 2030 |
What are the competitive dynamics and potential disruptions?
- Emerging competitors: Acalabrutinib (AstraZeneca) and Zanubrutinib (BeiGene) received approvals for similar indications and are priced competitively.
- Pipeline drugs: Second-generation BTK inhibitors with potentially superior safety profiles could lead to shifting market shares.
- Regulatory landscape: Strategies incentivizing biosimilar uptake or price regulation may accelerate price reductions.
Summary of key data points
| Data Point |
Details |
| Current US list price per 140 mg capsule |
$460–$480 |
| Average annual cost for typical patient dose |
~$503,200 |
| Global sales in 2022 |
$7.8 billion |
| Patent expiry year (expected) |
2027 |
| Major competitors |
Acalabrutinib, Zanubrutinib |
| Estimated future market value (2030) |
$4-6 billion |
Key Takeaways
- Ibrutinib remains a dominant therapy in its indication but faces growing competition and patent losses.
- Pricing is likely to decline gradually over the next five years, influenced by biosimilar entry, competitive pressures, and payer negotiations.
- Long-term growth prospects depend on pipeline developments, label expansions, and regulatory policies.
- Market share shifts are probable as second-generation inhibitors demonstrate improved profiles.
- Stakeholders need to monitor patent challenges, biosimilar developments, and regulatory changes to adjust pricing strategies accordingly.
FAQs
1. When is the patent for Ibrutinib expected to expire?
Patent protections are projected to expire around 2027, opening the pathway for biosimilar competition.
2. How might biosimilars impact Ibrutinib pricing?
Biosimilars can reduce list prices by 20-40%, leading to lower net prices for payers and patients.
3. Are there approved biosimilars for Ibrutinib?
As of 2023, no biosimilar products have received approval for Ibrutinib; biosimilar entrants are in late-stage development or submission phases.
4. What are the main drivers of cost for Ibrutinib therapy?
Drug price, dosage, treatment duration, and negotiated discounts influence overall cost.
5. Which competitors are most likely to threaten Ibrutinib's market share?
Acalabrutinib and Zanubrutinib are leading second-generation BTK inhibitors with similar efficacy and potentially better safety profiles.
Sources
[1] IQVIA, "Worldwide Medicine Sales Data," 2022
[2] FDA Drug Approvals and Patent Data, 2022–2023
[3] Evaluate Pharma, "2023 Market Data," 2023
[4] Market Access Reports, "Biosimilar Impact on Oncology Drugs," 2023
